Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.

 

3. Report: Valeant’s hostile takeover hopes fade as Allergan war continues

Aesthetics devices maker Allergan threw another punch in the ongoing war with hostile buyer Valeant Pharmaceuticals, calling out alleged problems with Valeant’s latest earnings report.

The ongoing war between the aggressive buyer and uninterested device maker has taken a toll on Valeant, and some negative sentiments from shareholders may signal the downfall of the unrequited $53 billion offer, one analyst said. Read more

2. Boston Scientific reveals federal probe of BridgePoint medical buy, sales

Boston Scientific informed investors this week that it’s under investigation by the U.S. Attorney for the District of New Jersey over a cardiology devices company acquired 2 years ago.

Boston Scientific reported in its most recent quarterly report that it was served with a subpoena for information about its 2012 acquisition of BridgePoint Medical as well as sales and training activities for BridgePoint’s CrossBoss CTO-crossing catheter and Stingray CTO re-entry system. Read more

1. FTC wants more data on Medtronic-Covidien deal, but analysts aren’t worried

The anti-inversion commotion in Washington, D.C., is “more bark than bite” and unlikely to turn into reform in time to damage Medtronic’s $43 billion deal with Covidien, according to analysts with Morgan Stanley.

Democrats have won support from the White House for efforts to penalize companies that relocate their corporate headquarters outside of the U.S. in order to benefit from lower tax rates, but Republicans won’t be so eager to play along, the analysts wrote. Read more